Study #2022-0459
A phase II trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in patients with relapsed B-cell NHL
MD Anderson Study Status
Enrolling
Treatment Agent
Mosunetuzumab, Polatuzumab vedotin, Tafasitamab, Lenalidomide
Description
To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL
Study phase:
Phase II
Physician name:
Jason Westin
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.